Engineered immune cells take aim at returning leukemia
NCT ID NCT03326921
First seen Nov 15, 2025 · Last updated Jun 20, 2026 · Updated 27 times
Summary
This early-phase trial tests a new type of immunotherapy for children and adults whose acute leukemia has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered donor immune cells (T cells) that are designed to recognize and attack a protein called HA-1 found on leukemia cells. The study will enroll 24 participants to find the safest dose and see if the cells can be successfully made and given.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HA-1-specific T cells (immune cells engineered to recognize and attack leukemia cells)
What this could lead to
If successful, this could offer a new treatment option for leukemia that returns after a stem cell transplant, potentially improving outcomes for patients with limited alternatives.
What could go wrong
This is an early phase 1 trial with only 24 participants, so safety and dosing are still being evaluated. The therapy may not work for everyone, and there are risks of side effects like graft-versus-host disease or immune reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.